A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma.

Maarten R Seefat David G J CucchiStijn DirvenKaz GroenSonja ZweegmanHedwig M Blommestein

Published in: Cancers (2021)

Cost-effectiveness ratios of novel agents were generally above current willingness-to-pay thresholds. To ensure access, cost-effectiveness should be improved or cost-effectiveness ratios above current thresholds should be accepted.

Keyphrases

multiple myeloma
combination therapy
replacement therapy